About Fathom Therapeutics
Fathom Therapeutics is a private company based in New York, New York, incorporated in 2023 in Delaware. It has reported $38,215,324 raised in two offerings on Form D since November 2023. Its chief executive is Huafeng Xu.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Mar 20, 2026 | $31,130,335of $59.6M target | 29 | $1.0M | Equity, Offering of Series A and Series A-1 Preferred Stock (collectively "Series A") and the underlying shares of Common Stock issuable upon conversion of Series A.Rule 506(b) | Form D ↗ |
| Nov 13, 2023 | Nov 16, 2023 | $7,084,989fully sold | 31 | $228K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $38,215,324 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Fathom Therapeutics's Form D filed Mar 20, 2026.
KL
HX